
Global HEARTS Initiative – Trinidad and Tobago Implementation and Scale Up MOH Overview

Virtual Course on the Implementation of the HEARTS Technical Package in Primary Care Health Teams


Dr. Rohit Doon Advisor Public Health, Ministry of Health Trinidad and Tobago.

Country Population Profile –

(Estimated 2017)



MoH – Public Health Clinical Infrastructure



Description of MoH Primary Health Care Clinical Infrastructure

)	
-	-	
- T	-	

Type of Facility	Catchment Population	Hours of Operation
Outreach Health Centre Primary Care / CMOH	Up to 5000	Nurse Led – 1-5 days/week Physician Led – 1-2 days/week 8 am – 4 pm
Health Centre Primary Care / CMOH	Up to 30,000	Physician Led; 5 days / week 8 am – 4 pm
Enhanced Health Centre Primary Care / CMOH	Up to 50,000	Physician Led; 5 days / week Several concurrent clinics in progress from Monday - Friday
District Health Facility Primary Care / CMOH	Up to 120,000	Physician Led; 24 hr service; 7 days per week

Total 103 Health Centres

Distribution of NCD Mortality




NCD	NUMBER OF DEATHS 2015	% OF DEATHS 2015	2015 CAUSE SPECIFIC DEATH RATES (PER 100,000 POPULATION)
HEART DISEASE	2673	25	198.0
DIABETES	1497	14	110.9
CANCER	1390	13	103.0
CEREBRO-VASCULAR DISEASE	1069	10	79.2
NCD'S OVERALL	6629	62	491.2

Intermediate/Biologic Risk Factors (PANAM STEPS NCD Risk Factor Survey 2011)





- Prevalance of Elevated blood pressure 26.3% (had or were currently on anti-hypertensive medication)
 29.8% of males 23.1% females)
- Prevalence of elevated total cholesterol -

 $\frac{23.5\%}{(≥ 6.2 \text{ mmol/L or being currently on medication for raised cholesterol})}$ 28.3% in males 18.9% in females



ELEMENTS FACILITATING POLITICAL COMMITMENT





HEARTS Site

- Arima District Health Facility
- Sangre Grande
 Enhanced Health Centre
- Freeport Health Centre 11,000
- Oxford Street Health Centre
- Scarborough
- Health Centre

40,000

Population

60,000

- 22,000
 - 16,000

149,000

Total





Chronic Disease Assistance Form

1000	Physician's Copy MINISTRY OF HEALTH Chronic Disease Assistance Plan (C-DAP)				
R _x I	R _x Date// Patient's Name				
	Item	Directions for use	Qty. Disp.] ID #	۲ <u></u>
51	Insulin 70 / 30 [Novo]	Directions for use	Qty. Disp.	F	or Physician's Use Only
52	Insulin 70 / 30 [Lilly]				
53	Insulin N.P.H [Novo]				
54	Insulin N.P.H [Lilly]				
55	Insulin Regular [Novo]			Physician's	Name (Block Letters)
56	Insulin Regular [Lilly]				
58	BGM Strips - Abbot				
59	BGM Strips - Roche			Physician's	Signature
21	Syringes			DI	
2	Gliclazide 80mg Tablets			Physician's	Address
3	Glibenclamide 5mg Tablets				
4	Metformin 500mg Tablets				
5	Acetazolamide 250mg Tablets				
6	Betaxolol 0.25% Eye Drops		1		
7	Pilocarpine 2% Eye Drops				
8	Pilocarpine 4% Eye Drops				
9	Timolol 0.5% Eye Drops	and the second			All of the second secon
10	Atenolol 50mg Tablets		2 million		
11	Bendrofluazide 5mg Tablets		1 Martin and a	Disper	ising Pharmacist's Use Only
12	Enalapril 10mg Tablets				
40	Frusemide 40mg Tablets	- Address Address	1.00		
13	Lisinopril 10mg Tablets	and and the second	the second	Pharmacy N	
14	Methyldopa 250mg Tablets			I nar macy is	lanc
16	Nifedipine SR 20mg Tablets			License #	
18	Digoxin 0.125 mg Tablets			License main	
19	Glyceryl Trinitrate 0.5mg Tablets				
20	Isosorbide Dinitrate 10mg Tablets			Pharmacist	
22	A.S.A 81mg Tablets			I nar macist	Itallic
57	Simvastatin 40mg Tablets			Reg No	
23	Ibuprofen 200mg Tablets			Reg. Ho. an	
24	Diclofenac SR 100mg Tablets	Carlos and		Date Dispen	sed: / /
25	Amitryptilline 25mg Tablets			- Date Dispen	dd mm yyyy
26	Benzhexol 2mg Tablets	Seattle Street and	1 million		
42	Chlorpromazine 100mg Tablets	and a start of a start	Long St. 1	Fan	Repeat Prescriptions Only
28	Fluoxetine 20mg Capsules		1.2	FOF	Repeat r rescriptions Only
29	Sulpiride 50mg Tablets				
30	Trifluperazine 5mg Tablets			-	
31	Terazosin 2mg Tablets			Physician's	
32	Terazosin 5mg Tablets			-	
33	Salbutamol Inhaler				
34	Beclomethasone Inhaler				DAP R _x # Name
35	Prednisolone Syrup	and the second			A
36	Prednisolone 5mg Tablets				
37	Spacer Device (Pediatric)			For	r Patient / Recipient Only
43	Phenytoin Sodium 100mg Capsules				
44	Phenytoin Sodium 125mg /5ml Suspension	and the second se			
45	Sodium Valporate 200mg Tablets				ainiant's Signature
46	Sodium Valporate 200mg/5ml Suspension		-	- Fatient / Ke	cipient's Signature
47	Carbamazepine 200mg Tablets				
	Carbamazepine 100mg/5ml Suspension				cipient's ID Card #
49	Levodopa/Carbidopa 100/25mg Tablets Omeprazole 20mg Capsules			- L'attent / Re	cipient s in Caru #

Hypertension Algorithm

ALGORITHM 1 – ACCEPTABLE ALGORITHM 1 – PREFERRED If BP > 140/90 with No Comorbidities. If BP > 140/90 with No Comorbidities. If uncontrolled (sBP>140mmHg OR dBP>90mmHg) after one If uncontrolled (sBP>140mmHg OR dBP>90mmHg) after one month, move to next step; month, move to next step; ACE - Lisinopril 10mg, plus • ARB - Irbesartan 150mg (Candesartan 16mg)*, plus CCB - Amlodipine 5mg CCB - Amlodipine 5mg Step Step ACE - Lisinopril 20mg, plus • ARB - Irbesartan 300mg (Candesartan 32mg)*, plus CCB - Amlodipine 10mg Step CCB - Amlodipine 10mg Step 2 ACE - Lisinopril 40mg, plus • ARB - Irbesartan 300mg (Candesartan 32mg)*, plus CCB - Amlodipine 10mg CCB - Amlodipine 10mg Step 3 Step 3 Add Chlorthalidone 12.5mg ACE - Lisinopril 40mg, plus CCB - Amlodipine 10mg • ARB - Irbesartan 300mg (Candesartan 32mg)*, plus Bendrofluazide 2.5 mg or Hydrochlorothiazide Step CCB - Amlodipine 10mg 12.5mg Step 4 Increase to Chlorthalidone 25 mg • If Uncontrolled, REFER Step 5 If Uncontrolled REFER Step 5

AVOID ACE inhibitors and ARBs in Pregnancy

Candesartan may be substituted if Irbesartan unavailable

Impact of CDAP Program on CVD



- During the 2004 to 2008 period CVD mortality rates declined significantly.
 - Age adjusted mortality has dropped 18.8% since 2004
 - Even though data on population coverage of CVD treatments and risk factors prevalence over this period is scant the decline is likely due to an increase in treatment availability.
- Several CVD control strategies were employed (CABG, PCI, Health Promotion and Drug treatment).
- The drop in CVD mortality rates observed in Trinidad and Tobago are most likely the result of availability of multiple treatments available, the Chronic Disease Assistance Program (CDAP Drug Management) program is the one that accounts for the larger percentage.

What Are We Implementing at a Population-base Level and What is the Progress?			
Component	Expected result	Strategic priority to the present (May 2019)	Progress score
Trinidad and To in fighting the	FCTC, fully implemented.	 Tobacco Control Legislation passed 2009 Health Professionals trained to design Tobacco Cessation programs integrated into PHC Tobacco Education program implemented Tobacco Control Unit established The 5 key interventions of the FCTC, including the availability of smoking cessation in the first level of care implemented. 	4



What Are We Implementing at a Population-based Level and What is the Progress?

Component	Expected result	Strategic priority to the present (May 2019)	Progress score
Salt	Regulations to reduce salt consumption implemented	 Salt study integrated into the 2019 STEPS Survey Instrument Survey of local food sources, high in sodium Nutrition Standard for Food served to children in schools developed Parliament adopted CARICOM's Six Point Policy for Promoting Healthy Diets which includes salt reduction TTO participating in a pilot program to reduce salt consumption in CARICOM States 	2




Component	Expected result	Strategic priority to the present (May 2019)	Progress score (1 to 5; 5 advanced progress status)
Industrially produced Trans fats	Regulations to eliminate trans fats implemented	TTO National NCD Plan identified eliminsation of Trans Fats as a priority action.	1
		Parliament of the GORTT, adopted CARICOM's Six Point Policy for pPromoting Healthy Diets which includes elimination of Trans Fats from the food supply	

Progress in the implementation of the HEARTS technical package

Component Implementati	2025 on of technical package fo	Strategic priority to the present (May 2019) or CVD management with emphasis on ention for the primary care level	Progress score hypertension and
Strengthening health systems for improved management of CVD	HEARTS chronic care model implemented in at least 70% of primary health care facilities 80% increase in proportion of persons controlled	HEARTS institutionalized in at least one (1) Primary Care Health Centre in each RHA to improve treatment of HTN in	2
Healthy lifestyles counseling	Self-management /patient education based for management and care of HTN and Diabetes implemented for 80% of persons with NCDs (guided by HEARTS Package)		PHSSPUKI Second

Progress in the implementation of the HEARTS technical package



Monitoring Of Data Quality And Measurements

- Targets and indicators selected and agreed on
- Monitoring framework established and used
- Evaluation team identified. Evaluation conducted 1 year after the program
- Articles and research papers on TTHI written. At least one article published in a peer reviewed journal
- Public forum to share the results of the program conducted after 1 year





Public forum to share the results of the program conducted after 1 year

System For Monitoring The Quality Of Measurement Data



Component	Expected results for 2025	Strategic priority to the present (May 2019)	Progress score
Education and certification of providers	Providers have performance protocols and are certified for blood pressure measurement	Providers have performance protocols and are certified for blood pressure measurement	2
Blood pressure measuring devices	Policy is defined, regulations and mechanisms are established to enforce regulations for validated devices	Automated devices are used Manual devices are used AND are calibrated and validated	2

System for monitoring the quality of measurement data

Component	Expected results for 2025	Strategic priority to the present (May 2019)	Progress score
Blood pressure measuring devices	Policy defined. Regulations and mechanisms established for validating devices	Standardised electronic HTN devices are used AND are calibrated and validated as per policy	
Clinical audit	Clinical audit system implemented, as part of a quality management system	Functional clinical audit system that regularly evaluates clinical documents, adherence to blood pressure measurement protocols and therapeutic algorithm.	2
System for monitoring	Monitoring of key variables to evaluate	Mean of systolic and diastolic blood pressure	2
	the quality of measurements	Mean of diastolic blood pressure and standard deviations.	2
		Prevalence of terminal digit 0, 2, 4, 6, 8 if using manual devices	2



Where we are implementing and what population we are covering with the HEARTS Initiative

Implementatio n site	Coverage: Baseline	Coverage goal for 2020	Control: Baseline	Control Goal for 2020
Sangre Grande Enhanced Health Centre	36%	50%	20%	50%
Oxford Street	In progress	20% increase	In progress	30% increase
Scarborough	17%	40%	In progress	30% increase
Freeport Health Centre	In progress	20% increase	In progress	30% increase
Arima District Health Facility	20%	40%	In progress	30% increase

Roadmap for HEARTS to become a model of care within Primary Care in 2025 and coverage of the entire population

Approval of the National Treatment Protocol and Algorithm for Hypertension in PHC Training of Staff in RHAs in the Use of the TTO Treatment Protocol and Algorithm for Hypertension in PHC

Phased introduction of Treatment Guidelines and Algorithm in PHC

Capacity Building for TTHI Implementation in Regional Settings: Team Based Care, Healthy Lifestyle Establishment of M&E mechanism and Surveillance system

-core standardised indicators ; Minimum data sets -Registries Updating of Drug Formulary and Realign Purchasing Intention of Hypertensive Drugs

Increase access to health technology/ equipment for managing HTN in PHC settings

Scale up of TTHI with each RHA



Elements that are facilitating the implementation

- High level political commitment
- Buy in and commitment from RHAs
- Funding for scale up available
- Mechanism for access to essential medicine is in place (Chronic Disease Assistance Programme)
- Technical support accessible

Roadmap for HEARTS to become a model of care within Primary Care in 2025 and coverage of the entire population

